Abbott Laboratories (ABT)’s Insider Daniel Starks Bought 40,037 Shares; Enpro Industries (NPO)’s Sentiment Is 1.4

EnPro Industries, Inc. designs, develops, makes, and markets engineered industrial products worldwide. The company has market cap of $1.55 billion. The companyÂ’s Sealing Products segment offers metallic, non-metallic, and composite material gaskets; dynamic seals; compression packings; resilient metal seals; elastomeric seals; hydraulic components; expansion joints; flange sealing and isolation products; pipeline casing spacers/isolators; casing end seals; modular sealing systems for sealing pipeline penetrations; hole forming products; manhole infiltration sealing systems; heavy-duty truck wheel-end component systems; bellows and bellows assemblies; pedestals for semiconductor manufacturing; and polytetrafluoroethylene products. It has a 2.93 P/E ratio. This segmentÂ’s products are used in the chemical and petrochemical processing, petroleum extraction and refining, pulp and paper processing, power generation, food and pharmaceutical processing, primary metal manufacturing, mining, water and waste treatment, heavy-duty trucking, aerospace, medical, filtration, and semiconductor fabrication industries.

The Abbott Laboratories’s director Daniel Starks obtained – 40,037 shares of Abbott Laboratories, based on the stock price per share of $60.7 for share . These insider purchased shares recently had a value of approximately $2.43 million U.S Dollars . This trade was pretty sizable one, so clearly it won’t go undiscovered. At present, he owns a total of 6.98 million shares or 0.40% of the company’s market cap (share price times the number of shares outstanding).

Since September 22, 2017, it had 0 insider purchases, and 10 insider sales for $35.12 million activity. $27,213 worth of stock was sold by PEDERSON MICHAEL J on Friday, February 16. Shares for $14.27 million were sold by Fussell Stephen R. The insider Watkin Jared sold $17,609. Salvadori Daniel Gesua Sive sold $1.56 million worth of stock or 28,319 shares. $2.69M worth of Abbott Laboratories (NYSE:ABT) was sold by Ford Robert B on Tuesday, January 30. 27,733 Abbott Laboratories (NYSE:ABT) shares with value of $1.73M were sold by Blaser Brian J. Shares for $2.74M were sold by Contreras Jaime.

The stock decreased 0.36% or $0.22 during the last trading session, reaching $60.33. About 8.33M shares traded or 16.88% up from the average. Abbott Laboratories (NYSE:ABT) has risen 15.90% since March 1, 2017 and is uptrending. It has underperformed by 0.80% the S&P500.

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on April, 18. They expect $0.58 EPS, up 20.83% or $0.10 from last year’s $0.48 per share. ABT’s profit will be $1.01 billion for 26.00 P/E if the $0.58 EPS becomes a reality. After $0.74 actual EPS reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts -21.62% negative EPS growth.

Abbott Laboratories manufactures and sells health care products worldwide. The company has market cap of $105.36 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon. It has a 224.28 P/E ratio. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

Investors sentiment decreased to 0.87 in Q3 2017. Its down 0.01, from 0.88 in 2017Q2. It fall, as 47 investors sold Abbott Laboratories shares while 563 reduced holdings. 111 funds opened positions while 421 raised stakes. 1.21 billion shares or 0.79% less from 1.22 billion shares in 2017Q2 were reported. Los Angeles Capital Mgmt And Equity Rech Incorporated holds 0.13% or 428,732 shares. Plancorp Llc holds 0.3% in Abbott Laboratories (NYSE:ABT) or 19,141 shares. Boston Advsr Limited Liability Company holds 0.09% or 78,107 shares in its portfolio. Hemenway Limited Liability Company stated it has 267,738 shares or 2.98% of all its holdings. The Illinois-based Ubs Asset Mngmt Americas Inc has invested 0.4% in Abbott Laboratories (NYSE:ABT). Mairs Power Inc owns 4.57 million shares. Afam Capital has 0.86% invested in Abbott Laboratories (NYSE:ABT). Factory Mutual Insurance Com invested 0.35% in Abbott Laboratories (NYSE:ABT). Symphony Asset Mngmt Limited Liability Com reported 0.53% stake. Hancock holds 0.01% in Abbott Laboratories (NYSE:ABT) or 4,278 shares. Ssi Mngmt reported 0.03% in Abbott Laboratories (NYSE:ABT). Van Cleef Asset Managementinc holds 0.18% or 12,610 shares. Meyer Handelman Commerce holds 100,321 shares or 0.24% of its portfolio. Peak6 Investments Ltd Partnership has 0.01% invested in Abbott Laboratories (NYSE:ABT) for 52,857 shares. Hayek Kallen Inv Mngmt has 25,633 shares.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories has $90 highest and $4 lowest target. $63.81’s average target is 5.77% above currents $60.33 stock price. Abbott Laboratories had 105 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Hold” rating by BMO Capital Markets given on Thursday, July 20. Cowen & Co maintained Abbott Laboratories (NYSE:ABT) rating on Tuesday, August 15. Cowen & Co has “Buy” rating and $55.0 target. The firm has “Buy” rating given on Saturday, August 29 by Deutsche Bank. The firm has “Neutral” rating by JP Morgan given on Friday, October 6. Jefferies maintained it with “Buy” rating and $47 target in Tuesday, March 15 report. Morgan Stanley maintained the shares of ABT in report on Thursday, October 19 with “Equal-Weight” rating. Cowen & Co maintained the stock with “Buy” rating in Wednesday, October 18 report. Edward Jones upgraded the shares of ABT in report on Tuesday, June 21 to “Buy” rating. The stock of Abbott Laboratories (NYSE:ABT) has “Neutral” rating given on Thursday, October 19 by Citigroup. Jefferies maintained the shares of ABT in report on Wednesday, October 18 with “Buy” rating.

Analysts await EnPro Industries, Inc. (NYSE:NPO) to report earnings on May, 7. They expect $0.87 EPS, up 97.73% or $0.43 from last year’s $0.44 per share. NPO’s profit will be $18.55 million for 20.82 P/E if the $0.87 EPS becomes a reality. After $0.67 actual EPS reported by EnPro Industries, Inc. for the previous quarter, Wall Street now forecasts 29.85% EPS growth.

The stock decreased 3.85% or $2.9 during the last trading session, reaching $72.46. About 194,936 shares traded or 40.52% up from the average. EnPro Industries, Inc. (NPO) has risen 42.29% since March 1, 2017 and is uptrending. It has outperformed by 25.59% the S&P500.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter:


Recent Posts